Gilead Gets FDA Nod to Extend Remdesivir Use to Renal Disease

Gilead Sciences says the FDA has approved a supplemental new drug application for the use of Veklury (Remdesivir) in Covid patients with severe renal impairment.

• Company says Veklury is now the first and only approved antiviral Covid treatment that can be used across all stages of renal disease

To view the source of this information, click here

To contact the reporter on this story:
Lin Cheng in New York at lcheng97@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.